COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3-zeta; and 4-1BB Signaling Domains in Pediatric and Young Adult Patients with Relapsed and/or Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia

Protocol No
IIT-TALANO-CART-ALL
Principal Investigator
Julie-An Talano
Phase
I
Summary
The purpose of this project is to find new ways to treat relapsed and/or refractory blood or lymph cancers. In this study, a virus (lentivirus) is used to introduce a gene that creates a protein (called a chimeric antigen receptor or CAR) on the surface of T cells, a type of white blood cell (WBC) that fights infection and eliminates cancer cells. CAR-20/19-T cells are made from white blood cells that are removed from your blood by a procedure called apheresis.
Description
Phase 1 Study of CAR-20/19-T Cells in Pediatric and Young adult Patients with R/R B Cell ALL
Participating Institutions
Children's Wisconsin
Froedtert Hospital
Status
OPEN TO ACCRUAL